A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 1995

Conditions
HIV Infections
Interventions
DRUG

Glycovir

DRUG

Zidovudine

Trial Locations (22)

14260

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

27514

Unc Aids Crs, Chapel Hill

60611

Northwestern University CRS, Chicago

60612

Rush Univ. Med. Ctr. ACTG CRS, Chicago

60640

Weiss Memorial Hosp., Chicago

63112

St. Louis ConnectCare, Infectious Diseases Clinic, St Louis

90033

USC CRS, Los Angeles

94110

Ucsf Aids Crs, San Francisco

98104

University of Washington AIDS CRS, Seattle

Unknown

Alabama Therapeutics CRS, Birmingham

Stanford CRS, Palo Alto

University of Colorado Hospital CRS, Aurora

Univ. of Miami AIDS CRS, Miami

Cook County Hosp. CORE Ctr., Chicago

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

Methodist Hosp. of Indiana, Indianapolis

Washington U CRS, St Louis

Beth Israel Med. Ctr. (Mt. Sinai), New York

Univ. of Rochester ACTG CRS, Rochester

Wake County Health and Human Services CRS, Raleigh

Univ. of Cincinnati CRS, Cincinnati

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

G D Searle

INDUSTRY

collaborator

Glaxo Wellcome

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH